We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Biotech Researchers Invited to Use an Automated, High-Capacity Target Capture-Sequencing Service

By LabMedica International staff writers
Posted on 11 Aug 2011
Researchers in need of DNA sequencing data can avail themselves of a new service that provides completely automated, high capacity, target capture-sequencing data, and streamlines sample preparation for targeted next-generation sequencing.

The new service, called targeted resequencing, is an innovation of Beckman Coulter Genomics (Danvers, MA, USA), a leading provider of genomic services and nucleic acid purification products.

The benefits of targeted resequencing include reduced sequencing, data storage, and processing requirements; more samples can be sequenced - increased throughput, decreased cost per sample; enhanced discovery of functional variations responsible for a disease; higher throughput and faster project turnaround times; greater reproducibility of sequence data; and decreased sample processing time from weeks to days.

Functionally, the service relies on the combination of “Agilent SureSelect Target Enrichment” technology with Beckman Coulter’s “SPRIworks Fragment Library System” for automated library construction and “Biomek Laboratory Automation Workstation” for liquid handling. More...
This platform provides high quality, reproducible samples ready for sequencing. Beckman Coulter Genomics automated target capture solution allows for whole exome capture or custom targeting of genomic regions of interest. Sequencing on the Illumina GAII or HiSeq 2000 instruments provides accurate data with reduced project turnaround time resulting from workflow automation and flexible sample multiplexing options.

“By automating this pipeline and maximizing our target capture sequencing capacity, we are able to offer our customers a high-throughput solution, with faster project turnaround times and reproducible sequencing data,” said Dr. William Donahue, manager of molecular biology for Beckman Coulter Genomics. “Our LIMS [laboratory information management system] sample tracking also enables large numbers of samples to be processed at the same time, significantly reducing the risk of sample mix-up that exists in a manual process.”

Results are delivered via a secure FTP site or are shipped on a portable hard drive depending upon the size of the dataset.

Related Links:

Beckman Coulter Genomics







Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.